Jefferies Financial Group Inc. Purchases New Position in GoodRx Holdings, Inc. $GDRX

Jefferies Financial Group Inc. acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 26,447 shares of the company’s stock, valued at approximately $132,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in shares of GoodRx by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 8,624,872 shares of the company’s stock valued at $38,036,000 after buying an additional 251,833 shares during the last quarter. Petrus Trust Company LTA boosted its stake in GoodRx by 7.4% in the first quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company’s stock valued at $13,967,000 after acquiring an additional 216,926 shares in the last quarter. 8 Knots Management LLC purchased a new position in shares of GoodRx during the first quarter worth about $8,106,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of GoodRx by 16.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock worth $8,324,000 after purchasing an additional 236,896 shares in the last quarter. Finally, EVR Research LP lifted its holdings in shares of GoodRx by 243.3% in the 1st quarter. EVR Research LP now owns 1,300,000 shares of the company’s stock valued at $5,733,000 after purchasing an additional 921,337 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total transaction of $95,084.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.53% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on GDRX shares. TD Cowen dropped their price target on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Wall Street Zen downgraded GoodRx from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Mizuho lowered their target price on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. UBS Group reduced their price target on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Finally, Raymond James Financial cut shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.52.

GoodRx Trading Up 0.4%

NASDAQ:GDRX opened at $2.84 on Friday. GoodRx Holdings, Inc. has a 12-month low of $2.61 and a 12-month high of $5.81. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock’s 50 day simple moving average is $3.63 and its 200-day simple moving average is $4.11. The firm has a market cap of $963.98 million, a P/E ratio of 31.56, a PEG ratio of 1.46 and a beta of 1.19.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $196.03 million for the quarter, compared to analyst estimates of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.GoodRx’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 earnings per share. GoodRx has set its FY 2025 guidance at EPS. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.